GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Degree of Operating Leverage

GALT (Galectin Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Galectin Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Galectin Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Galectin Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Degree of Operating Leverage Chart

Galectin Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galectin Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Galectin Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Galectin Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galectin Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Galectin Therapeutics's Degree of Operating Leverage falls into.


;
;

Galectin Therapeutics Degree of Operating Leverage Calculation

Galectin Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -38.957 (Mar. 2025) / -37.644 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.0349/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Galectin Therapeutics  (NAS:GALT) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Galectin Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Galectin Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Executives
Harold H. Shlevin director, officer: Chief Executive Officer C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Zordani Richard A. Jr. director 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
Kary Eldred director 2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman director 712 LAKEWAY DRIVE, KELLER TX 76248
Joel Lewis director 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Jack W Callicutt officer: Chief Financial Officer 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
James C Czirr director 4908 SOUTH ASHTON COURT, SPOKANE WA 99223
10x Fund, L.p. 10 percent owner 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz director 235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio director 5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein director, 10 percent owner 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes officer: Chief Medical Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Marc Rubin director C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Peter G Traber director, officer: President and CEO 430 THAMER LANE, HOUSTON TX 77025